October 10, 2022
Crinetics Announces October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces October 2022 inducement grants: the stock options were granted as inducements material to 11 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
October 6, 2022
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
The UK Medicines and Healthcare products Regulatory Agency has granted CRN04777 an “Innovation Passport” for the treatment of congenital hyperinsulinism.
October 3, 2022
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
Crinetics appoints Dana Pizzuti, M.D., a 30-year pharmaceutical industry veteran, to the newly created role of chief development officer
September 12, 2022
Crinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces September 2022 inducement grants: the stock options were granted as inducements material to 13 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
September 8, 2022
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Crinetics Pharmaceuticals management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022